Bristol-Myers Squibb (BMY) Tops Q1 EPS by 16c; reaffirms guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $55.53 +1.52%
EPS Growth %: +10.3%
Financial Fact:
Total Expenses: 3.36B
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +10.3%
Financial Fact:
Total Expenses: 3.36B
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of $1.58, $0.16 better than the analyst estimate of $1.42. Revenue for the quarter came in at $11.49 billion versus the consensus estimate of $10.92 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2026 EPS of $6.05-$6.35, versus the consensus of $6.26. Bristol-Myers Squibb sees FY2026 revenue of $46-47.5 billion, versus the consensus of $47.12 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- Alphabet to replace Verizon in the Dow Jones Industrial Average
- Cboe launches binary options suite tied to Mini-S&P 500 Index
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
